Skip to main content

Table 2 Median values (ranges) of measures of irradiation of both lungs excluding iGTV, at baseline and after re-optimization, and two-sided significances of changes in distributions of these measures following re-optimization

From: Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer

Dose-volume measure At baseline After MDHeart reduction After VHeart-50-Gy reduction After VLAwall-63-Gy reduction
EQD2Lung-mean* 13.7 Gy (8.0, 16.8 Gy) 13.9 Gy (7.2, 16.6 Gy)
p = 0.03
13.7 Gy (7.7, 16.7 Gy)
p = 0.07
14.1 Gy (8.0, 16.8 Gy)
p = 0.86
Mean lung dose 15.7 Gy (9.4, 19.5 Gy) 15.8 Gy (8.5, 19.3 Gy)
p = 0.03
15.7 Gy (9.1, 19.4 Gy)
p = 0.06
16.0 Gy (9.4, 19.5 Gy)
p = 0.89
VLung-10-Gy** 47.2% (29.0,70.9%) 46.3% (27.6, 73.9%)
p = 5 × 10–3
46.5% (29.0, 76.5%)
p = 0.16
47.5% (29.0, 77.4%)
p = 0.88
VLung-20-Gy 27.2% (15.6, 34.4%) 28.1% (13.6, 34.8%)
p = 0.98
26.4% (14.9, 34.5%)
p = 0.30
26.4% (15.6, 34.9%)
p = 0.94
VLung-30-Gy 17.1% (7.9, 23.7%) 16.4% (6.7, 24.5%)
p = 0.59
16.7% (7.7, 23.7%)
p = 8 × 10–3
16.6% (7.9, 23.7%)
p = 0.72
VLung-50-Gy 7.0% (2.6, 12.2%) 6.9% (2.2, 14.4%)
p = 1.00
7.0% (2.4, 12.6%)
p = 0.05
7.5% (2.6, 12.2%)
p = 0.30
  1. *Equivalent dose in 2 Gy fractions averaged across both lungs minus iGTV
  2. **The fraction of both lungs minus iGTV receiving ≥ 10 Gy